ID   HHUA
AC   CVCL_3866
SY   HHUA-1
DR   CLO; CLO_0050885
DR   BioSample; SAMN03472264
DR   cancercelllines; CVCL_3866
DR   Cosmic; 713497
DR   Cosmic; 735333
DR   Cosmic; 1177619
DR   Cosmic; 1223488
DR   Cosmic; 1241346
DR   Cosmic; 1622898
DR   Cosmic; 1696758
DR   Cosmic; 2030474
DR   DepMap; ACH-002026
DR   IARC_TP53; 2377
DR   RCB; RCB0658
DR   TOKU-E; 4122
DR   Wikidata; Q54887500
RX   PubMed=2429643;
RX   PubMed=2448191;
RX   PubMed=6532401;
RX   PubMed=6706228;
RX   PubMed=8105795;
RX   PubMed=9436037;
RX   PubMed=9573483;
RX   PubMed=10457904;
RX   PubMed=15901131;
WW   Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
WW   Info; RCB; -; https://cell.brc.riken.jp/en/wp-content/uploads/pdf/announcement/RCB0658_en.pdf
CC   Problematic cell line: Possibly contaminated. HHUA (distributed by RCB) and SNG-M (distributed by JCRB) share similar STR profiles and have been established by the same research group. While HHUA was described in 1984 and SNG-M in 1977 it has not been possible to establish which of the two cell lines are derived from each other. Thus it has been decided to consider them as being sister cell lines originating from the same donor.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00628.
CC   Population: Japanese.
CC   Doubling time: 34 hours (Note=At 5th passage), 30 hours (Note=At 15th passage) (PubMed=6706228); 30 hours (PubMed=6532401); 28 hours (PubMed=10457904).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ala138Val (c.413C>T); ClinVar=VCV000184863; Zygosity=Unspecified (PubMed=8105795).
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): DepMap=ACH-002026; RCB=RCB0658
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,11
ST   D16S539: 10,12
ST   D18S51: 12,18,19
ST   D21S11: 29,30
ST   D3S1358: 14,15
ST   D5S818: 9,12,13,14 (DepMap=ACH-002026)
ST   D5S818: 9,13,14 (RCB=RCB0658)
ST   D7S820: 10,13 (RCB=RCB0658)
ST   D7S820: 10,13,14 (DepMap=ACH-002026)
ST   D8S1179: 11,13
ST   FGA: 21,22
ST   Penta D: 8,11
ST   Penta E: 11,13
ST   TH01: 6,7
ST   TPOX: 8,9
ST   vWA: 17,18,19 (RCB=RCB0658)
ST   vWA: 17,19,20,21 (DepMap=ACH-002026)
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1707 ! SNG-M
OI   CVCL_S914 ! SNG-P
SX   Female
AG   52-54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 27
//
RX   PubMed=2429643; DOI=10.1111/j.1447-0756.1986.tb00192.x;
RA   Ishiwata I., Ishiwata C., Nozawa S., Ishikawa H.;
RT   "CA125 production by gynecologic tumors in vitro and its modulation
RT   induced by dibutyl cyclic adenosine monophosphate.";
RL   Asia Oceania J. Obstet. Gynaecol. 12:285-290(1986).
//
RX   PubMed=2448191; DOI=10.1016/0090-8258(88)90151-5;
RA   Ishiwata I., Ishiwata C., Soma M., Ono I., Nakaguchi T., Ishikawa H.;
RT   "Tumor angiogenic activity of gynecologic tumor cell lines on the
RT   chorioallantoic membrane.";
RL   Gynecol. Oncol. 29:87-93(1988).
//
RX   PubMed=6532401; DOI=10.1111/j.1447-0756.1984.tb00721.x;
RA   Ishiwata I., Ishiwata C., Ishikawa H.;
RT   "Effects of estradiol-17 beta and progesterone on cell proliferation
RT   and differentiation of the human endometrial carcinoma cell line
RT   (HHUA) in vitro.";
RL   Asia Oceania J. Obstet. Gynaecol. 10:531-538(1984).
//
RX   PubMed=6706228; DOI=10.1016/0090-8258(84)90212-9;
RA   Ishiwata I., Ishiwata C., Soma M., Arai J., Ishikawa H.;
RT   "Establishment of human endometrial adenocarcinoma cell line
RT   containing estradiol-17 beta and progesterone receptors.";
RL   Gynecol. Oncol. 17:281-290(1984).
//
RX   PubMed=8105795; DOI=10.1002/mc.2940080303;
RA   Enomoto T., Fujita M., Inoue M., Nakazawa-Miyamoto A., Tanizawa O.,
RA   Nomura T.;
RT   "Alterations of the Rb gene and its association with Ki-ras activation
RT   and p53 inactivation in endometrial adenocarcinoma.";
RL   Mol. Carcinog. 8:132-137(1993).
//
RX   PubMed=9436037;
RA   Soma M., Ishiwata I., Ishiwata C., Nakaguchi T., Ono I., Kiguchi K.,
RA   Hashimoto H., Tachibana T., Ishikawa H., Nozawa S.;
RT   "Tissue reconstruction of gynecologic tumor cells in the rotation
RT   culture system.";
RL   Hum. Cell 10:175-181(1997).
//
RX   PubMed=9573483;
RA   Ishiwata I., Tokieda Y., Ishiwata C., Okane N., Iguchi M., Sato K.,
RA   Ishikawa H.;
RT   "Effects of feeder cells (human cancer cell lines) on the development
RT   of mouse embryos by co-culture.";
RL   Hum. Cell 10:237-246(1997).
//
RX   PubMed=10457904;
RA   Ishiwata I., Sudo T., Kiguchi K., Ishikawa H.;
RT   "Tumor angiogenesis factors produced by cancer cells.";
RL   Hum. Cell 12:37-46(1999).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//